BioMedPartners raise CHF75m fundBasel-based BioMedPartners announes the first round of BioMedInvest III, its third equity venture capital fund at CHF75m. Up to 16 private Swiss, German and EU early-to-midstage ventures might be selected … more ➔
Germany to allow GMOs without labellingWhile GMO opponents are protesting, German Research Minister Johanna Wanka has recommended to rely on modern genetic engineering methods such as genome editing to develop the next generation of crops. more ➔
Inventiva raises €48m in Euronext IPO Raising €48m by the sale of 5.7 million shares at €8.50, French Inventiva S.A. is set to secure capital to further its late-stage products until H1/2019. more ➔
Vifor Pharma expands ChemoCentryx partners...Swiss Galenica subsidiary Vifor Pharma has licensed commercialisation rights for ChemoCentryx Inc’s complement C5a receptor (C5aR ) blocker Avacopan (CCX168) in Asia and the Middle East. The drug is … more ➔
Novimmune partners with LegoChem Bioscienc...Swiss antibody specialist Novimmune has entered a R&D collaboration on antibody drug conjugates (ADC) with the South Korean conjugation chemistry expert LegoChem Biosciences. more ➔
Oncoinvent closes US$25m private placementAfter having issued a patent on its lead cancer treatment Radspherin, Oslo-based Oncoinvent A/S has bagged the funding needed to go ahead to proof-of-concept. more ➔
AMR: EU Commission awards €45,000Vytenis Andriukaitis, Commissioner for Health and Food Safety, has awarded the EU Health Award for NGOs fighting Antimicrobial Resistance to BEUC for lobbying to reduce the threat of antimicrobial resistance … more ➔
Prexton Therapeutics gets €29m cash inje...Merck Serono spin-out Prexton Therapeutics has closed a Series B financing round cashing in US$31m for pushing Phase II testing of its Parkinson’s compound PXT002331. more ➔
Biotechs concerned over EPO rulesLife Sciences stakeholders in Europe and abroad are voicing their concerns about the European Patent Offices’ initiative to shorten the time for the examination of patents from up to 56 months to 12 … more ➔
Biotech investor plans IPO in LondonBritish life science investor Arix Biosciences is planning an IPO at London Stock Exchange. The London-based investor aims to raise £100m (€116m) to reinvest in innovations in medical science. more ➔
